EYA4 and breast carcinoma: Interestingly, disruption of EYA4 expression was implied to contribute to cancer progression including lung cancer [23], hepatocellular carcinoma [24], breast cancer [25], esophageal squamous cell carcinoma [17], and bladder cancer [26].